Drug Combination Details
| General Information of the Combination (ID: C12909) | |||||
|---|---|---|---|---|---|
| Name | Parthenolide NP Info | + | Epirubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Parthenolide along with Epirubicin chemotherapy drug could improve cytotoxicity and apoptosis and reduces IC50. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Anticancer and apoptotic activities of parthenolide in combination with epirubicin in mda-mb-468 breast cancer cells. Mol Biol Rep. 2020 Aug;47(8):5807-5815. | |||
